Basel, Switzerland – February 10, 2026 — BaseLaunch, a platform partnering with scientists and entrepreneurs to launch, fund, and build early biotech ventures, announced today the pharmaceutical giant Pfizer has joined the Basel-based incubator, bringing the total number of leading pharma company partners to seven.
Since its inception almost a decade ago, BaseLaunch has supported 27 biotech companies across various modalities and indications, with several of them having entered Phase II clinical trials. Adding Pfizer as a partner helps BaseLaunch further develop its portfolio companies, which have collectively raised over $1 billion (USD).
”BaseLaunch’s roster of biotech heavy hitters continues to grow and adding new partnerships will significantly benefit our early-stage biotech ventures allowing for further growth and greater impact in the biotech industry.
Stephan EmmerthDirector at BaseLaunch
The addition of Pfizer comes just two months after BaseLaunch announced its sixth global partner, proving the platform’s potential in fostering innovation.
Read more here.
